Keyphrases
6-mercaptopurine (6-MP)
31%
6-Thioguanine (6-TG)
7%
Acute Lymphoblastic Leukemia
93%
Acute Pancreatitis
6%
Asparaginase-associated Pancreatitis
30%
Bloodstream Infection
5%
Cerebrospinal Fluid
10%
Chemotherapy
6%
Childhood Acute Lymphoblastic Leukemia
89%
Childhood Leukemia
7%
Children with Cancer
6%
Confidence Interval
13%
Consolidation Treatment
6%
Fish Oil
5%
Flow Cytometric
5%
Hazard Ratio
8%
Healthcare Professionals
7%
High-dose Methotrexate (HD-MTX)
12%
Hypertriglyceridemia
6%
Induction Treatment
10%
Infections in children
6%
L-asparaginase
38%
Leukemia
5%
Leukemia Therapy
16%
Leukemic Blast
9%
Maintenance Therapy
19%
Mercaptopurine
11%
Methotrexate
10%
Methyltransferase Activity
5%
Minimal Residual Disease
7%
Odds Ratio
6%
Older Adults
13%
Oncology Studies
5%
Osteonecrosis
18%
Pancreatitis
20%
Pediatric Hematology
25%
Pediatric Oncology
25%
Pegaspargase
9%
Pegylated Asparaginase
11%
Pharmacokinetics
5%
Ponte
6%
Randomized Controlled Trial
8%
Relapse Risk
10%
Risk Factors
10%
Survivors
6%
T-cell Acute Lymphoblastic Leukemia (T-ALL)
6%
Thiopurine Methyltransferase
12%
Thromboembolism
13%
Thrombosis
10%
Working Diagnosis
7%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
100%
Asparaginase
43%
Bloodstream Infection
5%
Bone Marrow Toxicity
6%
Bone Necrosis
7%
Chemotherapy
9%
Hepatotoxicity
5%
Hyperlipidemia
5%
Lymphatic Leukemia
5%
Mercaptopurine
34%
Methotrexate
22%
Minimal Residual Disease
7%
Pancreatitis
19%
Pharmacokinetics
5%
Polyethylene Glycol
7%
Randomized Controlled Trial
5%
Remission
7%
Thiopurine Methyltransferase
8%
Thromboembolism
12%
Thrombosis
6%
Tioguanine
13%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
96%
Adolescent
9%
Asparaginase
36%
Bloodstream Infection
5%
Bone Necrosis
12%
Cerebrospinal Fluid
7%
Drug Megadose
7%
Hazard Ratio
5%
Leukemia
6%
Lymphoid Leukemia
5%
Malignant Neoplasm
9%
Mercaptopurine
13%
Methotrexate
9%
Pancreatitis
33%
Pediatric Hematology
16%
Pediatric Oncology
16%
Pediatrics
6%
Randomized Controlled Trial
7%
Systematic Review
6%
Thromboembolism
7%